Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Legend Biotech Corporation
Legend Biotech Corporation News
Legend Biotech Corporation Quantitative Score
About Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Legend Biotech Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Legend Biotech Corporation Financials
Table Compare
Compare LEGN metrics with: | |||
|---|---|---|---|
Earnings & Growth | LEGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LEGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LEGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LEGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Legend Biotech Corporation Income
Legend Biotech Corporation Balance Sheet
Legend Biotech Corporation Cash Flow
Legend Biotech Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Legend Biotech Corporation Executives
| Name | Role |
|---|---|
| Mr. Tim Roberts | Global Compliance Officer |
| Mr. Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply |
| Ms. Elaine Qian | Vice President & Global Head of Human Resources |
| Ms. Caroline LeCates Paul | Associate Director of Investor Relations |
| Dr. Mythili Koneru M.D., Ph.D. | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Tim Roberts | Global Compliance Officer | Male | -- | |
| Mr. Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply | Male | -- | |
| Ms. Elaine Qian | Vice President & Global Head of Human Resources | Female | -- | |
| Ms. Caroline LeCates Paul | Associate Director of Investor Relations | Female | -- | |
| Dr. Mythili Koneru M.D., Ph.D. | Chief Medical Officer | 1979 | -- |